» Download Public Reports
55 reports
- Company report
- June 2012
- 5 pages
... Of screening. As for presenting absolute risk reductions, the Number needed to screen To prevent one breast cancer has been advocated by some as a good and simple tool for communicating the effec- tiveness ...
February 2013
... Company, entered into an agreement granting orphan europe the exclusive rights for the commercialization and distribution of graspa for the treatment of acute lymphoblastic leukemia (all) and acute ...
September 2012
... From Climate and malaria vectri results projects seasonal forecasts future vector borne diseases such as malaria have a \climatic niche" both the vector and parasite are in uenced by weather however ...
May 2012
... Slovenia, spain, switzerland, the netherlands, uk the research pursued the objective to contribute to increase awareness among countries on the needs of persons with this spinal cord injury, as well ...
March 2012
... It is compulsory for every health care provider to report newly detected cancer cases diagnosed during: clinical, pathological, morphological, other lab, and medical examinations as well as cases diagnosed ...
June 2012
... And observational studies (pre-ct or ct) 30% ind/sme act. 2: Translational research in other major diseases cardiovascular diseases Discovery research to reveal novel targets for cardiovascular ...
September 2012
... Components (3, 4), such as the intake of fat, may be positively related to the risk of prostate cancer (5 7). Several biologically plausible mechanisms may underlie the association between dietary fat intake ...
September 2012
... Of gastroenterology department of clinical medicine, university of bologna, italy circlecopyrt ueg. 2012 colorectal cancer epidemiology 2 case study: participation in the eu funding schemes | presentation by luigi ...
June 2012
... New drugs / new classes / new strategies Working on the Cure Treatment as prevention management of hiv disease in countries with high income: a changing scenario (with also a current and future ...
» Purchase Premium Reports
(From $ 3 495 - $ 6 995)
About 400 reports
- $ 6 995
- Industry report
- February 2013
- by Global Data
Evista (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Evista (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Odanacatib (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Protelos (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Protelos (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Reclast (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Reclast (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Forteo (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Forteo (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
